Arbutus Biopharma (ABUS-Q) Stock Predictions - Stockchase
WATCH LIST
7
Arbutus Biopharma (ABUS-Q)

ON STOCKCHASE SINCE Aug 2014

Formerly Tekmira. (Aug 2015)

Consumer Products

Arbutus Biopharma

ABUS-Q

2 watching          
Join the Discussion

Arbutus Biopharma (ABUS-Q) SAVE Apr, 22, 2019, 3:35 pm

3.14 0.04 (1.37%)

What the experts are saying about ABUS-Q



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Arbutus Biopharma(ABUS-Q) 

January 28, 2015

They are known for their Ebola treatment but people lost interest in them and the stock started to sell off. They then made a deal, but he wonders if it was made in order to prop up the share price. Wouldn’t Buy the stock here as it is pretty expensive and it is not proven yet.

Consumer Products
0 0 0 0 0
0 comments

They are known for their Ebola treatment but people lost interest in them and the stock started to sell off. They then made a deal, but he wonders if it was made in order to prop up the share price. Wouldn’t Buy the stock here as it is pretty expensive and it is not proven yet.

Consumer Products
0 0 0 0 0
0 comments
Fabrice Taylor

Publisher, The President's Club...

Price Price
$31.850
Owned Owned
No

COMMENT
Arbutus Biopharma(ABUS-Q) 

January 14, 2015

He has to be careful, because one drug could be a home run, but he has stayed away because it is so hard to predict how drugs will do through the whole approval process. You get a product that looks very promising through the first few stages of testing and trials. Right at the end, when they do the large scale trials, something turns up that hasn’t been seen in the smaller trials. To bring a new drug through the approval process is upwards of $1 billion. Because of this, they usually end up partnering with a big Pharma, and the value goes to the big Pharma.

Consumer Products
0 0 0 0 0
0 comments

He has to be careful, because one drug could be a home run, but he has stayed away because it is so hard to predict how drugs will do through the whole approval process. You get a product that looks very promising through the first few stages of testing and trials. Right at the end, when they do the large scale trials, something turns up that hasn’t been seen in the smaller trials. To bring a new drug through the approval process is upwards of $1 billion. Because of this, they usually end up partnering with a big Pharma, and the value goes to the big Pharma.

Consumer Products
0 0 0 0 0
0 comments
Michael Decter

President , Lawrence Decter Inve...

Price Price
$28.090
Owned Owned
No

COMMENT
Arbutus Biopharma(ABUS-Q) 

October 28, 2014

This company works on Ebola treatments. A stock like this is driven by news. There is seasonality to biotechs from June 23 to September 13, but in this case there is too much news going on.

Consumer Products
0 0 0 0 0
0 comments

This company works on Ebola treatments. A stock like this is driven by news. There is seasonality to biotechs from June 23 to September 13, but in this case there is too much news going on.

Consumer Products
0 0 0 0 0
0 comments
Brooke Thackray

Research A, Horizons ETFs (Canad...

Price Price
$20.210
Owned Owned
Unknown

SELL
Arbutus Biopharma(ABUS-Q) 

October 21, 2014

Doesn’t know exactly what is going to happen with the treatment of Ebola. The stock has had a tremendous run. They are miles away from being a valuation story at this point. If you have made some money in the stock, he would be inclined to take profits and move on.

Consumer Products
0 0 0 0 0
0 comments

Doesn’t know exactly what is going to happen with the treatment of Ebola. The stock has had a tremendous run. They are miles away from being a valuation story at this point. If you have made some money in the stock, he would be inclined to take profits and move on.

Consumer Products
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$20.170
Owned Owned
Unknown

DON'T BUY
Arbutus Biopharma(ABUS-Q) 

October 17, 2014

It is up a lot, but it is just so speculative.  It is not his cup of tea.  If the outbreak of Ebola starts to come under control, then this stock should decline back down.

Consumer Products
0 0 0 0 0
0 comments

It is up a lot, but it is just so speculative.  It is not his cup of tea.  If the outbreak of Ebola starts to come under control, then this stock should decline back down.

Consumer Products
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$24.600
Owned Owned
Unknown

DON'T BUY
Arbutus Biopharma(ABUS-Q) 

August 26, 2014

A play on ebola could have a nice kick up now, but looking at the financials, they have lost money in 8 out of the last 10 years. This does not bode well. Also, they are not at all close to getting the product into the market. The testing for their product was actually for another product, so they are going to have to have a certain amount of latitude in getting it out. He would prefer Alpha Pro Tech (APT-A).

Consumer Products
0 0 0 0 0
0 comments

A play on ebola could have a nice kick up now, but looking at the financials, they have lost money in 8 out of the last 10 years. This does not bode well. Also, they are not at all close to getting the product into the market. The testing for their product was actually for another product, so they are going to have to have a certain amount of latitude in getting it out. He would prefer Alpha Pro Tech (APT-A).

Consumer Products
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$20.930
Owned Owned
No

DON'T BUY
Arbutus Biopharma(ABUS-Q) 

August 12, 2014

Working on an experimental Ebola treatment. The biotech sector is probably the most volatile sector that you can get involved with. He would never buy just one biotech stock; he would buy a basket of 3, maybe 5. He wouldn’t touch this one. Too volatile and too risky.

Consumer Products
0 0 0 0 0
0 comments

Working on an experimental Ebola treatment. The biotech sector is probably the most volatile sector that you can get involved with. He would never buy just one biotech stock; he would buy a basket of 3, maybe 5. He wouldn’t touch this one. Too volatile and too risky.

Consumer Products
0 0 0 0 0
0 comments
Bill Carrigan

Technical , Getting Technical In...

Price Price
$20.250
Owned Owned
No

Showing 1 to 7 of 7 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days